nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—CHRM4—Monoamine GPCRs—DRD4—conduct disorder	0.0377	0.0377	CbGpPWpGaD
Fesoterodine—CHRM5—Monoamine GPCRs—DRD4—conduct disorder	0.0361	0.0361	CbGpPWpGaD
Fesoterodine—CHRM4—Amine ligand-binding receptors—DRD4—conduct disorder	0.0317	0.0317	CbGpPWpGaD
Fesoterodine—CHRM5—Amine ligand-binding receptors—DRD4—conduct disorder	0.0304	0.0304	CbGpPWpGaD
Fesoterodine—CHRM1—Monoamine GPCRs—DRD4—conduct disorder	0.0254	0.0254	CbGpPWpGaD
Fesoterodine—CHRM3—Monoamine GPCRs—DRD4—conduct disorder	0.0254	0.0254	CbGpPWpGaD
Fesoterodine—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.0251	0.0251	CbGpPWpGaD
Fesoterodine—CHRM4—Monoamine GPCRs—HTR2A—conduct disorder	0.0246	0.0246	CbGpPWpGaD
Fesoterodine—CHRM5—Monoamine GPCRs—HTR2A—conduct disorder	0.0236	0.0236	CbGpPWpGaD
Fesoterodine—CHRM1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0214	0.0214	CbGpPWpGaD
Fesoterodine—CHRM3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0213	0.0213	CbGpPWpGaD
Fesoterodine—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.0211	0.0211	CbGpPWpGaD
Fesoterodine—CHRM4—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0207	0.0207	CbGpPWpGaD
Fesoterodine—CHRM5—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0198	0.0198	CbGpPWpGaD
Fesoterodine—CHRM1—Monoamine GPCRs—HTR2A—conduct disorder	0.0166	0.0166	CbGpPWpGaD
Fesoterodine—CHRM3—Monoamine GPCRs—HTR2A—conduct disorder	0.0165	0.0165	CbGpPWpGaD
Fesoterodine—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.0164	0.0164	CbGpPWpGaD
Fesoterodine—CHRM4—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0162	0.0162	CbGpPWpGaD
Fesoterodine—CHRM5—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0155	0.0155	CbGpPWpGaD
Fesoterodine—CHRM1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0139	0.0139	CbGpPWpGaD
Fesoterodine—CHRM3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0139	0.0139	CbGpPWpGaD
Fesoterodine—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0138	0.0138	CbGpPWpGaD
Fesoterodine—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.0135	0.0135	CbGpPWpGaD
Fesoterodine—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.013	0.013	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Other—DRD4—conduct disorder	0.0113	0.0113	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.0112	0.0112	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0111	0.0111	CbGpPWpGaD
Fesoterodine—CHRM1—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0109	0.0109	CbGpPWpGaD
Fesoterodine—CHRM3—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0109	0.0109	CbGpPWpGaD
Fesoterodine—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0108	0.0108	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0107	0.0107	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—CGA—conduct disorder	0.00848	0.00848	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—CGA—conduct disorder	0.00812	0.00812	CbGpPWpGaD
Fesoterodine—CHRM4—G alpha (i) signalling events—DRD4—conduct disorder	0.00784	0.00784	CbGpPWpGaD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00771	0.00771	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00751	0.00751	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00748	0.00748	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00741	0.00741	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Other—HTR2A—conduct disorder	0.00735	0.00735	CbGpPWpGaD
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00728	0.00728	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.00728	0.00728	CbGpPWpGaD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00697	0.00697	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—SLC6A4—conduct disorder	0.00637	0.00637	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00624	0.00624	CbGpPWpGaD
Fesoterodine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0061	0.0061	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—DRD4—conduct disorder	0.00599	0.00599	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00597	0.00597	CbGpPWpGaD
Fesoterodine—CHRM5—G alpha (q) signalling events—HTR2A—conduct disorder	0.00588	0.00588	CbGpPWpGaD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.0058	0.0058	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—CGA—conduct disorder	0.00572	0.00572	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—CGA—conduct disorder	0.0057	0.0057	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.00564	0.00564	CbGpPWpGaD
Fesoterodine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00526	0.00526	CbGpPWpGaD
Fesoterodine—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.00522	0.00522	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00491	0.00491	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00489	0.00489	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00484	0.00484	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—CGA—conduct disorder	0.00479	0.00479	CbGpPWpGaD
Fesoterodine—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00475	0.00475	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—DRD4—conduct disorder	0.00475	0.00475	CbGpPWpGaD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00473	0.00473	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—CGA—conduct disorder	0.00459	0.00459	CbGpPWpGaD
Fesoterodine—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00455	0.00455	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—DRD4—conduct disorder	0.00455	0.00455	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—CGA—conduct disorder	0.00435	0.00435	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.0042	0.0042	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00419	0.00419	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—CGA—conduct disorder	0.00417	0.00417	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00415	0.00415	CbGpPWpGaD
Fesoterodine—CHRM1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00414	0.00414	CbGpPWpGaD
Fesoterodine—CHRM3—G alpha (q) signalling events—HTR2A—conduct disorder	0.00413	0.00413	CbGpPWpGaD
Fesoterodine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00407	0.00407	CbGpPWpGaD
Fesoterodine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00399	0.00399	CbGpPWpGaD
Fesoterodine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.0039	0.0039	CbGpPWpGaD
Fesoterodine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.0037	0.0037	CbGpPWpGaD
Fesoterodine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00369	0.00369	CbGpPWpGaD
Fesoterodine—CYP2D6—Biological oxidations—COMT—conduct disorder	0.00326	0.00326	CbGpPWpGaD
Fesoterodine—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.00324	0.00324	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—CGA—conduct disorder	0.00323	0.00323	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—CGA—conduct disorder	0.00322	0.00322	CbGpPWpGaD
Fesoterodine—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.00322	0.00322	CbGpPWpGaD
Fesoterodine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.0032	0.0032	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—DRD4—conduct disorder	0.0032	0.0032	CbGpPWpGaD
Fesoterodine—ABCB1—HIF-1-alpha transcription factor network—EP300—conduct disorder	0.00319	0.00319	CbGpPWpGaD
Fesoterodine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00319	0.00319	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—DRD4—conduct disorder	0.00319	0.00319	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.00319	0.00319	CbGpPWpGaD
Fesoterodine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00316	0.00316	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.00316	0.00316	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR ligand binding—HTR2A—conduct disorder	0.0031	0.0031	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR ligand binding—HTR2A—conduct disorder	0.00297	0.00297	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—CGA—conduct disorder	0.00293	0.00293	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—CGA—conduct disorder	0.00292	0.00292	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.0029	0.0029	CbGpPWpGaD
Fesoterodine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00274	0.00274	CbGpPWpGaD
Fesoterodine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00273	0.00273	CbGpPWpGaD
Fesoterodine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00271	0.00271	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—DRD4—conduct disorder	0.00268	0.00268	CbGpPWpGaD
Fesoterodine—ABCB1—Transmembrane transport of small molecules—GABRA2—conduct disorder	0.00263	0.00263	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—CGA—conduct disorder	0.00257	0.00257	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—DRD4—conduct disorder	0.00257	0.00257	CbGpPWpGaD
Fesoterodine—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.0025	0.0025	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—CGA—conduct disorder	0.00246	0.00246	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—DRD4—conduct disorder	0.00244	0.00244	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—DRD4—conduct disorder	0.00233	0.00233	CbGpPWpGaD
Fesoterodine—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00213	0.00213	CbGpPWpGaD
Fesoterodine—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.00212	0.00212	CbGpPWpGaD
Fesoterodine—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.0021	0.0021	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00209	0.00209	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR ligand binding—HTR2A—conduct disorder	0.00208	0.00208	CbGpPWpGaD
Fesoterodine—CHRM1—Circadian rythm related genes—EP300—conduct disorder	0.00207	0.00207	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—CGA—conduct disorder	0.00207	0.00207	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	0.00206	0.00206	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—WASF1—conduct disorder	0.00206	0.00206	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—WASF1—conduct disorder	0.00197	0.00197	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00181	0.00181	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—DRD4—conduct disorder	0.0018	0.0018	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	0.00179	0.00179	CbGpPWpGaD
Fesoterodine—CHRM4—GPCR downstream signaling—HTR2A—conduct disorder	0.00175	0.00175	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—CGA—conduct disorder	0.00173	0.00173	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—CGA—conduct disorder	0.00173	0.00173	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—CGA—conduct disorder	0.00171	0.00171	CbGpPWpGaD
Fesoterodine—CHRM5—GPCR downstream signaling—HTR2A—conduct disorder	0.00168	0.00168	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—DRD4—conduct disorder	0.00164	0.00164	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—DRD4—conduct disorder	0.00164	0.00164	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—DRD4—conduct disorder	0.00162	0.00162	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling by GPCR—HTR2A—conduct disorder	0.00159	0.00159	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling by GPCR—HTR2A—conduct disorder	0.00152	0.00152	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—DRD4—conduct disorder	0.00144	0.00144	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—WASF1—conduct disorder	0.00139	0.00139	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—WASF1—conduct disorder	0.00138	0.00138	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—DRD4—conduct disorder	0.00138	0.00138	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—WASF1—conduct disorder	0.00137	0.00137	CbGpPWpGaD
Fesoterodine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—conduct disorder	0.00136	0.00136	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—CGA—conduct disorder	0.00131	0.00131	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—CGA—conduct disorder	0.00124	0.00124	CbGpPWpGaD
Fesoterodine—CHRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.00118	0.00118	CbGpPWpGaD
Fesoterodine—CHRM3—GPCR downstream signaling—HTR2A—conduct disorder	0.00118	0.00118	CbGpPWpGaD
Fesoterodine—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	0.00117	0.00117	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling by GPCR—HTR2A—conduct disorder	0.00107	0.00107	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling by GPCR—HTR2A—conduct disorder	0.00107	0.00107	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	0.00106	0.00106	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—DRD4—conduct disorder	0.000971	0.000971	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—DRD4—conduct disorder	0.000968	0.000968	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—DRD4—conduct disorder	0.000958	0.000958	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—HTR2A—conduct disorder	0.000939	0.000939	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—COMT—conduct disorder	0.000933	0.000933	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—MAOA—conduct disorder	0.000926	0.000926	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—HTR2A—conduct disorder	0.0009	0.0009	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—CGA—conduct disorder	0.000808	0.000808	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—HTR2A—conduct disorder	0.000633	0.000633	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—HTR2A—conduct disorder	0.000631	0.000631	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—HTR2A—conduct disorder	0.000625	0.000625	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—COMT—conduct disorder	0.000592	0.000592	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—MAOA—conduct disorder	0.000588	0.000588	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—COMT—conduct disorder	0.000558	0.000558	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—MAOA—conduct disorder	0.000554	0.000554	CbGpPWpGaD
Fesoterodine—CHRM4—Signaling Pathways—EP300—conduct disorder	0.000498	0.000498	CbGpPWpGaD
Fesoterodine—CHRM5—Signaling Pathways—EP300—conduct disorder	0.000477	0.000477	CbGpPWpGaD
Fesoterodine—CHRM3—Metabolism—EP300—conduct disorder	0.0004	0.0004	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—COMT—conduct disorder	0.000365	0.000365	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—MAOA—conduct disorder	0.000362	0.000362	CbGpPWpGaD
Fesoterodine—CHRM1—Signaling Pathways—EP300—conduct disorder	0.000336	0.000336	CbGpPWpGaD
Fesoterodine—CHRM3—Signaling Pathways—EP300—conduct disorder	0.000334	0.000334	CbGpPWpGaD
Fesoterodine—CHRM2—Signaling Pathways—EP300—conduct disorder	0.000331	0.000331	CbGpPWpGaD
Fesoterodine—ABCB1—Metabolism—EP300—conduct disorder	0.000254	0.000254	CbGpPWpGaD
Fesoterodine—CYP2D6—Metabolism—EP300—conduct disorder	0.000239	0.000239	CbGpPWpGaD
Fesoterodine—CYP3A4—Metabolism—EP300—conduct disorder	0.000156	0.000156	CbGpPWpGaD
